Stocksigma LogoStocksigma Logo

Sheel Biotech Reports H1 FY27 Performance and Announces Major Orders

Sheel Biotech released its H1 FY27 investor presentation, reporting revenue from operations of ₹50.56 Cr, up 131.39% YoY, while EBITDA rose 208.31% YoY to

Sheel Biotech Reports H1 FY27 Performance and Announces Major Orders

Sheel Biotech Ltd · Investor Presentation · 17 Nov 2026, 9:29 pm

Sheel Biotech Reports H1 FY27 Performance and Announces Major Orders Sheel Biotech released its H1 FY27 investor presentation, reporting revenue from operations of ₹50.56 Cr, up 131.39% YoY, while EBITDA rose 208.31% YoY to ₹5.90 Cr with margins at 11.67%. PAT grew sharply to ₹3.39 Cr from ₹0.19 Cr in H1 FY26. The company announced order wins totaling ₹35.92 Cr, comprising a ₹21.39 Cr precision farming project in Jammu & Kashmir and a ₹14.53 Cr blueberry growing infrastructure project. Expansion into high-value berries remains a key focus area.

Original exchange filing (PDF)

More announcements from Sheel Biotech Ltd

All Sheel Biotech Ltd announcements